With offices in the US and Europe, ARCHIMED is a leading investment firm focused exclusively on the healthcare industries. Its mix of operational, medical, scientific and financial expertise allows the ARCHIMED team to serve as both a strategic and financial partner to European and North American small and middle-market businesses. Prioritized areas of focus include biopharmaceutical products & services, life science tools, medical devices & technologies, diagnostics, health technologies & software and consumer health. ARCHIMED helps partner companies internationalize, acquire, innovate, and expand their products and services.

Over the last twenty years, ARCHIMED’s leadership team has directly managed and invested in over eighty small to large-size healthcare companies globally, representing over €50 billion of combined value.

ARCHIMED manages over €5 billion in healthcare assets across its various funds. Since its inception, ARCHIMED has been a committed Impact investor, both directly and through its Eurêka Foundation.

The purpose of the shareholder engagement policy is to present the management company’s commitments as a shareholder or creditor and the procedures for exercising the rights attached to the interests it holds.

It explains the reasons for ARCHIMED’s commitment and its objectives as well as the measures leading to its implementation.

This report was drafted abiding by the provisions of Articles L.533-22 and R.533-16 of the Financial Currency Code.

1.1 Vote Scope

ARCHIMED has implemented a procedure for exercising voting rights in accordance with article 314-100 of the RGAMF. The voting policy is updated regularly and is available on the website or at the head office.

Regarding the 2021 financial year, the organization of voting rights is as follows: the investment teams are responsible for examining and analyzing the resolutions presented by the listed or unlisted companies in which the funds are invested.

1.2 Explanation of the choices made on the votes

ARCHIMED’s teams apply monitoring and analysis principles to each of the resolutions proposed to General Meetings.

These teams apply the voting policy in a pragmatic manner, taking into account the specificities of each holding (sector of activity, national regulations, size, shareholder structure, international context, economic and financial circumstances, etc.)

The ARCHIMED teams voted in favor of all the resolutions proposed to the General Meetings.

1.3 Voting rights organisation

ARCHIMED exercises its rights in accordance with its own voting policy, mainly in physical presence at General Meetings.

This report covers the votes exercised by ARCHIMED during the year 2021 in accordance with its voting scope.

2.1 Votes on Listed Securities

ARCHIMED has no holdings in any listed company.

2.2 Votes on unlisted securities

In fiscal year 2021, ARCHIMED attended 18 general meetings of unlisted companies held.

The ARCHIMED teams have analyzed all the resolutions submitted.

2.3 Votes derogating from the voting policy

During 2021, ARCHIMED voted in accordance with the principles defined in its voting policy. No vote was exercised in derogation of its principles.

2.4 Conflict of interest management

Potential conflicts of interest that may arise from the exercise of voting rights are governed by the policy for the prevention and management of conflicts of interest, as well as by good practices such as Chinese Wall.

During 2021, ARCHIMED did not detect any potential conflict of interest in connection with the exercise of voting rights.